Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT04208347Phase 3Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib, camrelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Ruijin Hospital. Started Dec 2019; status: active, not recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04208347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208347.